Monitoring steroid replacement therapy in children with congenital adrenal hyperplasia
- PMID: 27977405
- DOI: 10.1515/jpem-2016-0203
Monitoring steroid replacement therapy in children with congenital adrenal hyperplasia
Abstract
Background: The objective of this study was to compare the analysis of 17-hydroxyprogesterone (17-OHP) by radio-immunoassay (RIA) in serum with analysis by liquid chromatography tandem mass spectrometry (LC-MS/MS) on dried blood spot samples (DBSS) for monitoring therapy in children with congenital adrenal hyperplasia (CAH), and to investigate differences in 17-OHP values during the day.
Methods: Fourteen children (8 females), median age 4.2 (0.3-16.0) years, were studied. Serum samples and DBSS were drawn before hydrocortisone dosing.
Results: 17-OHP by LC-MS/MS in DBSS were highly correlated to 17-OHP by RIA in serum, r=0.956, p<0.01. A total of 26 three-time-point series were investigated. Using only the afternoon 17-OHP values to determine the hydrocortisone doses would have led to overdosing seven times and underdosing six times.
Conclusions: Good agreement was demonstrated between 17-OHP determination by RIA in serum and LC-MS/MS on DBSS. Multiple 17-OHP measurements per day are required to ensure sufficient hydrocortisone dose adjustment.
Similar articles
-
Therapy monitoring in congenital adrenal hyperplasia by dried blood samples.J Pediatr Endocrinol Metab. 2015 Jul;28(7-8):867-71. doi: 10.1515/jpem-2014-0303. J Pediatr Endocrinol Metab. 2015. PMID: 25781526
-
Diagnostic cut-offs of 17-hydroxyprogesterone by LC-MS/MS in children with non-classical congenital adrenal hyperplasia.J Endocrinol Invest. 2025 Jul;48(7):1623-1633. doi: 10.1007/s40618-025-02581-w. Epub 2025 Apr 15. J Endocrinol Invest. 2025. PMID: 40232622
-
Pharmacokinetic/Pharmacodynamic Evaluation of Hydrocortisone Therapy in Pediatric Patients with Congenital Adrenal Hyperplasia.J Clin Endocrinol Metab. 2020 Mar 1;105(3):dgaa071. doi: 10.1210/clinem/dgaa071. J Clin Endocrinol Metab. 2020. PMID: 32052005
-
Scalp hair 17-hydroxyprogesterone and androstenedione as a long-term therapy monitoring tool in congenital adrenal hyperplasia.Clin Endocrinol (Oxf). 2016 Oct;85(4):522-7. doi: 10.1111/cen.13078. Epub 2016 May 6. Clin Endocrinol (Oxf). 2016. PMID: 27061431
-
Biomarkers in congenital adrenal hyperplasia.Clin Endocrinol (Oxf). 2024 Oct;101(4):300-310. doi: 10.1111/cen.14960. Epub 2023 Aug 22. Clin Endocrinol (Oxf). 2024. PMID: 37608608 Review.
Cited by
-
Analysis of therapy monitoring in the International Congenital Adrenal Hyperplasia Registry.Clin Endocrinol (Oxf). 2022 Nov;97(5):551-561. doi: 10.1111/cen.14796. Epub 2022 Jul 11. Clin Endocrinol (Oxf). 2022. PMID: 35781728 Free PMC article.
-
Monitoring treatment in pediatric patients with 21-hydroxylase deficiency.Front Endocrinol (Lausanne). 2023 Feb 3;14:1102741. doi: 10.3389/fendo.2023.1102741. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 36843618 Free PMC article. Review.
-
Optimizing the Timing of Highest Hydrocortisone Dose in Children and Adolescents With 21-Hydroxylase Deficiency.J Clin Endocrinol Metab. 2022 Mar 24;107(4):e1661-e1672. doi: 10.1210/clinem/dgab826. J Clin Endocrinol Metab. 2022. PMID: 34788830 Free PMC article.
-
Diurnal salivary androstenedione and 17-hydroxyprogesterone levels in healthy volunteers for monitoring treatment efficacy of patients with congenital adrenal hyperplasia.Clin Endocrinol (Oxf). 2022 Jul;97(1):36-42. doi: 10.1111/cen.14690. Epub 2022 Feb 23. Clin Endocrinol (Oxf). 2022. PMID: 35150157 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical